Fluorescence-guided imaging technology company Lumicell is highlighting the first U.S. launch of its real-time breast cancer visualization platform, LumiSystem.
LumiSystem combines Lumisight, an optical imaging agent that fluoresces at sites of suspected cancerous tissue, and Lumicell Direct Visualization system, an imaging device that provides real-time fluorescence guidance for scanning the breast cavity during lumpectomy surgery, according to the firm.
The Investigation of Novel Surgical Imaging for Tumor Excision (INSITE) trial showed LumiSystem to have 84% diagnostic accuracy and that it improves surgical outcomes in 10% of patients, Lumicell said.